Aruna Dontabhaktuni

587 total citations
16 papers, 466 citations indexed

About

Aruna Dontabhaktuni is a scholar working on Oncology, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Aruna Dontabhaktuni has authored 16 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Molecular Biology and 3 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Aruna Dontabhaktuni's work include HER2/EGFR in Cancer Research (4 papers), Cancer Treatment and Pharmacology (3 papers) and Growth Hormone and Insulin-like Growth Factors (3 papers). Aruna Dontabhaktuni is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Cancer Treatment and Pharmacology (3 papers) and Growth Hormone and Insulin-like Growth Factors (3 papers). Aruna Dontabhaktuni collaborates with scholars based in United States, Japan and Germany. Aruna Dontabhaktuni's co-authors include Hagop Youssoufian, Johannes Nippgen, Abu T.M. Serajuddin, Madhu Pudipeddi, Alan E. Royce, Yatindra M. Joshi, Madhav Vasanthavada, J. Randolph Hecht, Diane Reidy‐Lagunes and Jonathan Schwartz and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Aruna Dontabhaktuni

16 papers receiving 457 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aruna Dontabhaktuni United States 10 216 152 144 53 52 16 466
Per Olov Gunnarsson Sweden 13 152 0.7× 140 0.9× 138 1.0× 61 1.2× 35 0.7× 33 529
Danish Mazhar United Kingdom 15 219 1.0× 167 1.1× 158 1.1× 23 0.4× 64 1.2× 56 698
Hongchuan Zhao China 14 129 0.6× 171 1.1× 128 0.9× 16 0.3× 34 0.7× 39 645
O. El-Ahmady Egypt 14 110 0.5× 219 1.4× 81 0.6× 22 0.4× 33 0.6× 34 573
Christopher Matheny United States 12 356 1.6× 109 0.7× 73 0.5× 99 1.9× 7 0.1× 23 695
Kristell Marzin Germany 11 196 0.9× 169 1.1× 312 2.2× 27 0.5× 47 0.9× 18 545
Fenlai Tan China 15 461 2.1× 235 1.5× 505 3.5× 16 0.3× 46 0.9× 39 809
Mukul Minocha United States 13 256 1.2× 151 1.0× 84 0.6× 75 1.4× 32 0.6× 32 612
Lynne P. Rutzky United States 12 212 1.0× 261 1.7× 41 0.3× 164 3.1× 34 0.7× 18 893

Countries citing papers authored by Aruna Dontabhaktuni

Since Specialization
Citations

This map shows the geographic impact of Aruna Dontabhaktuni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aruna Dontabhaktuni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aruna Dontabhaktuni more than expected).

Fields of papers citing papers by Aruna Dontabhaktuni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aruna Dontabhaktuni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aruna Dontabhaktuni. The network helps show where Aruna Dontabhaktuni may publish in the future.

Co-authorship network of co-authors of Aruna Dontabhaktuni

This figure shows the co-authorship network connecting the top 25 collaborators of Aruna Dontabhaktuni. A scholar is included among the top collaborators of Aruna Dontabhaktuni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aruna Dontabhaktuni. Aruna Dontabhaktuni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Elmeliegy, Mohamed, et al.. (2024). Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T‐Cell Engagers Development in Oncology. Clinical Pharmacology & Therapeutics. 116(3). 637–646. 9 indexed citations
2.
Doi, Toshihiko, Kohei Shitara, Takashi Kojima, et al.. (2016). A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 77(6). 1253–1262. 4 indexed citations
3.
Dontabhaktuni, Aruna, et al.. (2016). Gentamicin Renal Excretion in Rats: Probing Strategies to Mitigate Drug-Induced Nephrotoxicity. Pharmacology & Pharmacy. 7(1). 43–55. 4 indexed citations
4.
5.
Chiorean, E. Gabriela, Christopher Sweeney, Hagop Youssoufian, et al.. (2014). A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 73(3). 595–604. 50 indexed citations
6.
Doi, Toshihiko, et al.. (2014). Phase I study of olaratumab in Japanese patients with advanced solid tumors. Cancer Science. 105(7). 862–869. 33 indexed citations
7.
LoRusso, Patricia, Smitha Krishnamurthi, Hagop Youssoufian, et al.. (2013). Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Investigational New Drugs. 32(2). 303–311. 17 indexed citations
8.
Martell, Robert E., E. Gabriela Chiorean, Hagop Youssoufian, et al.. (2011). Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available.. Journal of Clinical Oncology. 29(15_suppl). TPS150–TPS150. 3 indexed citations
9.
10.
Kuenen, Bart C., Petronella O. Witteveen, Rita Ruijter, et al.. (2010). A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 16(6). 1915–1923. 66 indexed citations
11.
Zhu, Andrew X., RS Finn, Jayne Gurtler, et al.. (2010). A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 28(15_suppl). 4083–4083. 23 indexed citations
12.
Reidy‐Lagunes, Diane, Efsevia Vakiani, Marwan Fakih, et al.. (2010). Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology. 28(27). 4240–4246. 112 indexed citations
13.
Pudipeddi, Madhu, Madhav Vasanthavada, Aruna Dontabhaktuni, et al.. (2007). Measurement of Surface pH of Pharmaceutical Solids: A Critical Evaluation of Indicator Dye-Sorption Method and its Comparison With Slurry pH Method. Journal of Pharmaceutical Sciences. 97(5). 1831–1842. 62 indexed citations
14.
Dontabhaktuni, Aruna, et al.. (2006). Effects of Trimethoprim on the Clearance of Apricitabine, a Deoxycytidine Analog Reverse Transcriptase Inhibitor, and Lamivudine in the Isolated Perfused Rat Kidney. Journal of Pharmacology and Experimental Therapeutics. 319(2). 941–947. 15 indexed citations
15.
Taft, David R., et al.. (2006). Application of the Isolated Perfused Rat Kidney Model to Assess Gender Effects on Drug Excretion. Drug Development and Industrial Pharmacy. 32(8). 919–928. 2 indexed citations
16.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Per Olov Gunnarsson Breakdown of academic impact, for papers by Danish Mazhar Breakdown of academic impact, for papers by Hongchuan Zhao Breakdown of academic impact, for papers by O. El-Ahmady Breakdown of academic impact, for papers by Christopher Matheny Breakdown of academic impact, for papers by Kristell Marzin Breakdown of academic impact, for papers by Fenlai Tan Breakdown of academic impact, for papers by Mukul Minocha Breakdown of academic impact, for papers by Lynne P. Rutzky
Rankless by CCL
2026